All News

EULAR19.abstract.jpg (keep)

ACR Best Abstracts - Day 1

Jack Cush, MD

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of ACR 2022 (#ACRbest).



 

Read Article
meeting education

Don’t be ‘ticked’: TYK2 is not a JAK!

Janet Pope, MD, MPH, FRCPC

Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.

Read Article
Cancer.risk_.jpg

Avoid Abatacept in RA patients with a history of cancer?

Richard Conway, MBBChBAO, PhD

The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of cancer with tofacitinib than with TNF inhibitors. In this setting, two posters both reassure and raise a new cause for concern.

Read Article
question-mark-1872634_640.jpg

Do biologics help taper steroids in Adult Still’s Disease?

Bella Mehta, MBBS, MS

A Japanese large scale claims data study was able to collect 5-year data to study the treatment patterns in Still’s. In May 2019, intravenous tocilizumab was approved in Japan for Still’s disease. The study was designed to see patterns of steroid exposure before and after the approval of this therapy.

Read Article
creaky,joints

Creaky Joints Presentations at ACR Convergence 2022

Jack Cush, MD

The patient advocacy organization CreakyJoints will present 13 scientific posters at this year's ACR Convergence 2022 and 8 posters as part of the patient perspectives track. Below is a sampling of these scientific posters. 

Read Article
How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines: 💉Pre-vax: 💊csDMARDs - hold time 4 wks 💊bDMARDs -hold time of one dosing interval 💉Post-vax: hold DMARDs for 4 wks #ACR22 @rheumnow @rheumarhyme @doktora_ging https://t.co/MGc422EtIC
sheila RHEUMarampa ( View Tweet)
Patel @NaomiRheumMD et al. HbA1c in GiACTA. Tocilizumab assoc HbA1c reduction independent of steroids. Daily steroid dose assoc HbA1c @rheumnow #ACR22 Abstr#0461 https://t.co/9Nbewrpww8 https://t.co/NyeTyWICF6

Links:

Richard Conway RichardPAConway ( View Tweet)
🪞MIRROR RCT🪞 💊MTX ⬆️ response of Pegloticase in resistant gout pts (60% vs PBO 30.8%) 🦶Tophus resolution wk 52 >24 (cont. benefit💪🏻) 🧪⬇️ drug Ab with MTX ✅ No new IRs Abst#0001 #ACR22 @RheumNow #plenary https://t.co/8lPKQ0VGqC
Patricia Harkins DrTrishHarkins ( View Tweet)
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds @RheumNow https://t.co/a0tNFn5Wqr
Eric Dein ericdeinmd ( View Tweet)
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview @rheumnow #ACR22 https://t.co/luxDDluddM

Links:

TheDaoIndex KDAO2011 ( View Tweet)

Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Janet Pope Janetbirdope ( View Tweet)
Ab0343. #ACR22 Severe non-adherence of HCQ associated with FLARES, DAMAGE and DEATH 7.3% had "severe non-adherence" by HCQ levels Hazard ratio of flare 3.3, damage 4.26, and death 5.4 Not surprising, but very useful for pt discussion Checking HCQ levels are helpful! @Rheumnow https://t.co/S7P9oTPRGJ
Eric Dein ericdeinmd ( View Tweet)
Ab0344 #ACR22 CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1 400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200 Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL Social determinants didn't effect data >750ng/mL and >1000 predicted of 75% decr flare risk @Rheumnow #ACRBest https://t.co/p21rqnO4ym
Eric Dein ericdeinmd ( View Tweet)
Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh
TheDaoIndex KDAO2011 ( View Tweet)
Year in Review #acr22 Oral Surveillance: With ASCVD number needed to harm 16, only 223 without ASCVD Focus on risk stratification ⁦@RheumNow⁩ https://t.co/tJyha1WKfR
Eric Dein ericdeinmd ( View Tweet)
ORAL surveillance the big talking factor over the last year. NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease. @RheumNow #ACR22 #yearinreview #ACRBest

Julian Segan JulianSegan ( View Tweet)

Great start to year in review. Beginning with JAKinibs in the much talked about ORAL Surveillance study. Good Review of the mechanisms of action for JAKinibs @RheumNow #ACR22 https://t.co/IF0t4uSefj
Robert B Chao, MD doctorRBC ( View Tweet)
Abstr #0078 Ogdie et al found that - Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs - Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone @RheumNow #ACR22 https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)
Did You Know? FDA relaxed warnings on #sarcoma with #Forteo- can use more than 2 years ⁦@RheumNow⁩ #acr22 #acrreview #osteoporosis https://t.co/Xzr6TZIlWN
TheDaoIndex KDAO2011 ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×